Could SHMN be next to Rally, 2 of my alerts up 167 and 270 percent
StockEgg Newsletter
%3D
Special Alert – SHMN
My new big report: SHMN
What a day for small caps!! I hope you guys didn`t miss some of my recent alerts, CPMCF up 166% and NXPND up 165%
Could SHMN be the next huge winner Let me explain why SHMN may be the next big runner..
SHMN just announced the other day they expect to report Record 3rd Quarter revenue growth. The actual earnings haven`t come out yet but the company has released statements hinting to the record revenues.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. stated, “We started 2010 with a revenue increase of 600% for Q1 followed by a 1,000% percent increase for Q2. Q3 is expected to be the third consecutive quarter that the Company has achieved record quarterly revenue.”
When the actual earnings do come out and the street sees it, SHMN may see a huge rally!!
SHMN has the potential to be one of those that make explosive moves.
A bunch of big brand-name drugs, many that are popular with seniors, are set to go generic next year.
Popular medicines like Lipitor and Plavix.
Millions of people worldwide are currently using Lipitor to reduce their high cholesterol. Buying a generic version of this medicine could save patients and insurance companies so much money!
This is why SHMN may become a huge success.
SHMN is a generic pharma manufacturer that produces and markets generic drugs covering all major treatment categories.
Buying generic drugs is saving the U.S. health care system a great amount of money. According to IMS Health, generic medicines have saved the U.S. Health Care System $139.6 billion in 2009!
Why buy brand name common medicine for retail high prices if we can get the same thing at much cheaper prices
According to the U.S. Food and Drug Administration (FDA), generic drugs are identical or within an acceptable bioequivalent range to the brand name counterpart with respect to pharmacokinetic and pharmacodynamic properties.
Not just any generic drug can make it onto store shelves. Generic medicines must meet strict FDA guidelines for approval.
SHMN`s global headquarters are located in North America with manufacturing sites in India. India has a significant share in the global generics market and is ranked third in the world!
Three factors favoring SHMN`s manufacturing hub in India are:
1. strong marketing set up
2. low prices
3. the advantage of using the English language.
With domestic drug sales of almost $5 billion, Indian companies have developed a considerable service industry for the global pharma market.
Generic drugs already account for more than 70% of prescriptions dispensed in the U.S.!
“Generic pharmaceuticals continue to be one of the best buys in health care, said Paul Bisaro, Chairman of GPhAs Board of Directors. While prices for name brand prescriptions continue to rise year after year, generic prices have remained generally unchanged and in some cases have even declined as more competition enters the market.”
SHMN announced earlier this week that its India based pharma manufacturing facility sees a boost in its generic drug line as blockbuster drugs lose patent protection.
Branded products, many of them first-line therapies, will lose patent protection over the next 5 years in the US and present significant opportunities for product line expansion.
Over 49 such products will be affected by the end of 2013, including Topamax, Effexor XR, Lipitor, Plavix and Cymbalta!
SHMN expects to continue to expand its product lines and strengthen market penetration and revenue growth in key emerging markets including India, Africa, Latin America, and Southeast Asia.
SHMN is anticipating to report record revenue growth for the 3rd quarter of 2010.
This would be the third consecutive quarter of record revenue as sales of generic pharmaproducts continue to increase in both India and other targeted emerging markets. SHMN`s revenues have been very impressive this year.
Shailesh Shah, SHMN Vice President for Corporate Strategy, stated, “We started 2010 with a revenue increase of 600% for Q1 followed by a 1,000% percent increase for Q2. Q3 is expected to be the third consecutive quarter that the Company has achieved record quarterly revenue. Our strategy of focusing on the expansion of our market presence in India and select emerging pharmamarkets globally has been instrumental in achieving these results.”
Start your research on SHMN quickly at: www.sohm.com
Please do your due diligence and consult with a financial professional.
*********************************************************
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockEgg.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Full disclaimer can be read at http://www.StockEgg.com/disclaimer.htm
Release of Liability: Through use of this website viewing or using you agree to hold StockEgg.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. StockEgg.com has been compensated by Star Communications Worldwide forty five thousand dollars for a one week SHMN advertising services contract. StockEgg.com does not own any shares of SHMN. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. StockEgg..com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockEgg.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead StockEgg..com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. StockEgg.com is compliant with the Can Spam Act of 2003. StockEgg.com does not offer such advice or analysis, and StockEgg.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor`s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a `safe harbor` in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, StockEgg.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, StockEgg.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. StockEgg.com is not responsible for any claims made by the companies advertised herein, nor is StockEgg.com responsible for any other promotional firm, its program or its structure. Full disclaimer can be read at http://www.StockEgg.com/disclaimer.htm
Related posts:
- StockEgg.com – Mid Day Alert 10-27-2010
- SHMN.PK Introduction
- *** SHMN News Alert…Exclusive Agreement Announced! ***
- *** SHMN News Alert…Exclusive Agreement Announced! ***
- Mid Day Update for Wednesday – my alerts up 125 percent and 170